gastroenteropancreatic

gastroenteropancreatic

the unity of the gut and the pancreas.

gastroenteropancreatic cells
produce peptide hormones which help coordinate the physiological processes of digestion and carbohydrate metabolism. The cells are located in the intestinal mucosa and in the islets of Langerhans in the pancreas. The hormones produced include insulin, serotonin, glucagon, somatostatin.
References in periodicals archive ?
Gastrointestinal and pancreatic neuroendocrine tumors, also known as gastroenteropancreatic neuroendocrine tumors, are a rare type of cancer.
Frequent overexpression of HMGA1 and 2 in gastroenteropancreatic neuroendocrine tumours and its relationship to let-7 downregulation.
Somatostatin-receptor scintigraphy in gastroenteropancreatic tumors.
in 2015, a potential treatment for gastroenteropancreatic neuroendocrine tumors (GEP NETs).
Expression of somatostatin receptors and sympathoadrenal tumours High expression of Low expression Non-neoplastic receptors and of receptors pathology sympathoadrenal system tumours Phaeochromocytoma Breast Autoimmune carcinoma diseases Neuroblastoma Melanoma Granulomas Ganglioneuroma Lymphoma Thyroid-associated ophthalmopathy Paraganglioma Prostate Post-radiation cancer inflammatory disease Gastroenteropancreatic Non-small-cell Bacterial tumours (GEP) cancer infections (e.
Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
Recent studies have proposed the use of new TNM staging systems (European Neuroendocrine Tumor Society staging system) and biomarkers (Ki-67, cytokeratin 19, Cox-2, and epidermal growth factor receptor) to stratify gastroenteropancreatic NETs into categories with prognostic relevance.
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumors.
Neuroendocrine tumors of the gastroenteropancreatic system (NET-GEP) correlation between Ki-67 immunostaining, histological features and clinical behaviour.
Novartis, Basel, Switzerland, has announced that the Japanese health authority has approved Sandostatin LAR (octreotide acetate for injectable suspension) for the treatment of acromegaly and pituitary gigantism which is unresponsive to or unsuitable for surgery or other drug therapies, and for symptoms associated with gastrointestinal hormone secreting tumors (also known as gastroenteropancreatic (GEP) neuroendocrine tumors (NET), including carcinoid tumors, gastrinomas, and VIPomas (Vasoactive Intestinal Peptide- secreting tumors).
Combination therapy with octreotide and [alpha]-interferon: Effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors.
Efficacy and Safety of Lanreotide Depot vs Placebo in Patients With Neuroendocrine Tumor and a History of Carcinoid Syndrome and Prior Octreotide Therapy This presentation is a subanalysis of the ELECT study which tested treatment with lanreotide depot for symptomatic control of carcinoid syndrome in patients with gastroenteropancreatic neuroendocrine tumors against a placebo treatment.